Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation

• DOI: 10.1111/ctr.15420
• Publication Date: 2024-08-08T08:20:21Z
• Authors: Xinyi Huang; David Salerno; Danielle Kovac; Jenna Scheffert; Jessica Hedvat; Bayleigh Carver; Jason Choe; Tara Shertel; Melana Yuzefpolskaya; Paolo C. Colombo; Douglas L. Jennings
• Keywords: Immunosuppression; Basiliximab; Regimen

ABSTRACT Background There have been limited reports on immunosuppression strategies and outcomes in dual organ heart transplant populations, primarily from before the 2018 United Network for Organ Sharing (UNOS) allocation policy change. Recent data suggested that with heart–lung heart–liver transplants remained comparable new era, yet heart–kidney recipients worse 1‐year survival. Methods This single‐center retrospective study evaluated adult heart–kidney, heart–liver, September 2019 to May 2023. Immunosuppression regimen, infectious complications, graft were collected 12 months. Results A total of 36 patients (kidney n = 20, liver 9, lung 7) included this study. Basiliximab was most commonly employed induction strategy across groups (12/20 kidney, 4/9 liver, 7/7 lung). All triple at months posttransplant prednisone wean achieved one recipient. Infection complications frequently reported (95% 75% 100% group). One patient went back dialysis due focal segmental glomerulosclerosis. chronic allograft dysfunction reported, but no other severe biopsy‐proven rejection or retransplant reported. The survival 85% (17/20) 78% (7/9) 86% (6/7) recipients. Conclusion summarized real‐world